Peak Retirement Planning Inc. Invests $917,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Peak Retirement Planning Inc. purchased a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 10,238 shares of the medical equipment provider's stock, valued at approximately $917,000.

A number of other large investors have also made changes to their positions in LNTH. Park Avenue Securities LLC raised its position in shares of Lantheus by 26.4% during the fourth quarter. Park Avenue Securities LLC now owns 2,458 shares of the medical equipment provider's stock worth $220,000 after purchasing an additional 513 shares during the period. UMB Bank n.a. increased its stake in Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after purchasing an additional 134 shares in the last quarter. Dakota Wealth Management raised its holdings in Lantheus by 13.4% during the 4th quarter. Dakota Wealth Management now owns 3,468 shares of the medical equipment provider's stock worth $310,000 after buying an additional 409 shares during the period. Janney Montgomery Scott LLC lifted its stake in Lantheus by 40.9% in the fourth quarter. Janney Montgomery Scott LLC now owns 19,806 shares of the medical equipment provider's stock valued at $1,772,000 after buying an additional 5,753 shares in the last quarter. Finally, Blue Trust Inc. lifted its stake in Lantheus by 38.1% in the fourth quarter. Blue Trust Inc. now owns 1,981 shares of the medical equipment provider's stock valued at $177,000 after buying an additional 547 shares in the last quarter. Institutional investors own 99.06% of the company's stock.

Lantheus Stock Up 1.1%

Shares of NASDAQ:LNTH traded up $0.81 during midday trading on Thursday, reaching $74.99. The company had a trading volume of 382,941 shares, compared to its average volume of 986,509. Lantheus Holdings, Inc. has a 1-year low of $73.11 and a 1-year high of $126.89. The stock has a market cap of $5.19 billion, a PE ratio of 12.48 and a beta of 0.23. The business's 50 day moving average price is $93.04 and its 200 day moving average price is $91.78.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The firm had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm's revenue for the quarter was up .8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.69 earnings per share. On average, research analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the sale, the director now owns 440,399 shares of the company's stock, valued at $41,551,645.65. This represents a 10.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the company's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This represents a 8.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 63,109 shares of company stock valued at $6,016,046 over the last ninety days. 2.00% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on LNTH. Truist Financial dropped their price objective on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Finally, B. Riley decreased their price objective on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday, March 21st. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $132.67.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.